ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2023.
“We enter 2024 having made significant progress in realizing our strategic transformation. This is the year in which we expect all the key puzzle pieces to come together, setting us up for breakout growth to follow,” said David Fischel, Chairman and CEO.
“Our innovation strategy has a strong foundation, and we are pleased with where we stand. Regulatory submissions for our proprietary robotically-navigated ablation catheter have been made in both Europe and the United States, following stellar results from initial clinical use. We have begun formal testing of our smaller highly-accessible robot, and anticipate achieving European regulatory clearance mid-year followed by FDA clearance in the second half of the year. We also expect commercial launches later this year of a guidewire that expands our technology into several new indications, a comprehensive product ecosystem in China, and a digital surgery solution enabling broad operating room connectivity. These innovations collectively serve as a foundational product ecosystem for a high-growth medical robotics company poised to transform endovascular surgery. They are transformational as they structurally improve our clinical, commercial, financial, and strategic foundation.”
“Revenue growth amidst this transition has remained challenging. Revenue in 2023 was pressured by the loss of royalties and recurring shortages of catheters from our partner, highlighting the importance of overcoming key product dependencies. These headwinds counteracted growth in robotic system revenue for the year. System revenue remains lumpy, but we continue to benefit from a significant backlog and pipeline of orders. We were pleased in the fourth quarter to receive our first greenfield robotic system order from Germany in over a decade, and we anticipate continued growth in orders and system revenue as it becomes clear to physicians and hospitals that the supply of robotic catheters is secure.”
“We retain a strong balance sheet which allows us to bring our transformative product ecosystem to market, fund its commercialization, and reach profitability. We have multiple shots on goal for breakout growth in 2025.”
2023 Fourth Quarter and Full Year Financial Results
Revenue for the fourth quarter of 2023 totaled $4.6 million, compared to $7.3 million in the prior year fourth quarter. System revenue of $0.1 million and recurring revenue of $4.5 million, compared to $2.2 million and $5.1 million, respectively, in the prior year fourth quarter. System revenue was weaker than expected due to delays in hospital construction schedules but does not reflect our normalized expectation. Recurring revenue was in line with recent quarters. Revenue for the full year 2023 totaled $26.8 million compared to $28.1 million in 2022. Full year system revenue was $8.7 million compared to $6.8 million in the prior year, reflecting increased system deliveries. We started 2024 with system backlog of $14.7 million. Full year recurring revenue was $18.0 million compared to $21.3 million, reflecting the absence of catheter royalties received in the prior year and recurring catheter production shortages by our partner.
Gross margin for the fourth quarter and full year 2023 were approximately 60% and 56% of revenue, respectively. Full year gross margins were 79% for recurring revenue and 8% for system revenue. System gross margins reflect significant allocations of overhead and other direct expenses. Operating expenses in the fourth quarter were $8.0 million. Excluding $2.6 million in non-cash stock compensation expense, adjusted operating expenses in the current quarter were $5.4 million, down from the prior year adjusted operating expenses of $6.2 million. Adjusted operating expenses for the full year 2023 were $26.2 million, compared to $26.8 million in the prior year.
Operating loss and net loss for the fourth quarter of 2023 were ($5.3) million and ($5.0) million, respectively, compared to ($4.5) million and ($4.2) million in the previous year. Adjusted operating loss and adjusted net loss for the quarter, excluding non-cash stock compensation expense, were ($2.7) million, and ($2.4) million, respectively, compared to ($1.9) million and ($1.6) million in the previous year. For the full year 2023, adjusted operating loss of ($11.3) million and adjusted net loss of ($10.2) million compared to an adjusted operating loss of ($8.3) million and an adjusted net loss of ($7.8) million in the prior year. Negative free cash flow for the full year 2023 was ($9.1) million compared to ($10.8) million for the full year 2022.
Cash Balance and Liquidity
At December 31, 2023, Stereotaxis had cash and cash equivalents, including restricted cash, of $20.6 million and no debt.
Forward Looking Expectations
Stereotaxis anticipates double digit revenue growth for the full year 2024 driven by revenue recognition of system backlog and new system orders. Cognizant of the volatility in quarterly revenue and challenge in reliably anticipating revenue in any specific quarter, Stereotaxis is providing specific revenue guidance only for the first quarter of 2024 of approximately $7.0 million.
Stereotaxis’ balance sheet allows it to advance its transformative product ecosystem to market, fund its commercialization, and reach profitability without the need for additional financing.
Conference Call and Webcast
Stereotaxis will host a conference call and webcast today, March 4, 2024, at 4:30 p.m. Eastern Time. To access the conference call, dial 1-800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 7954885. Participants are asked to call 5-10 minutes prior to the start time. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at www.Stereotaxis.com.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly R. Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
| STEREOTAXIS, INC. | |||||||||||||||
| STATEMENTS OF OPERATIONS | |||||||||||||||
| (Unaudited) | |||||||||||||||
| (in thousands, except share and per share amounts) | Three Months Ended December 31, | Year Ended December 31, | |||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Revenue: | |||||||||||||||
| Systems | $ | 66 | $ | 2,196 | $ | 8,739 | $ | 6,845 | |||||||
| Disposables, service and accessories | 4,499 | 5,105 | 18,032 | 21,302 | |||||||||||
| Total revenue | 4,565 | 7,301 | 26,771 | 28,147 | |||||||||||
| Cost of revenue: | |||||||||||||||
| Systems | 749 | 1,985 | 8,058 | 5,802 | |||||||||||
| Disposables, service and accessories | 1,078 | 1,007 | 3,853 | 3,875 | |||||||||||
| Total cost of revenue | 1,827 | 2,992 | 11,911 | 9,677 | |||||||||||
| Gross margin | 2,738 | 4,309 | 14,860 | 18,470 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | 2,212 | 2,400 | 10,273 | 10,558 | |||||||||||
| Sales and marketing | 2,791 | 2,988 | 12,376 | 12,325 | |||||||||||
| General and administrative | 3,039 | 3,377 | 14,050 | 14,363 | |||||||||||
| Total operating expenses | 8,042 | 8,765 | 36,699 | 37,246 | |||||||||||
| Operating loss | (5,304 | ) | (4,456 | ) | (21,839 | ) | (18,776 | ) | |||||||
| Other income | 3 | - | 30 | - | |||||||||||
| Interest income, net | 261 | 302 | 1,096 | 484 | |||||||||||
| Net loss | $ | (5,040 | ) | $ | (4,154 | ) | $ | (20,713 | ) | $ | (18,292 | ) | |||
| Cumulative dividend on convertible preferred stock | (339 | ) | (338 | ) | (1,343 | ) | (1,343 | ) | |||||||
| Net loss attributable to common stockholders | $ | (5,379 | ) | $ | (4,492 | ) | $ | (22,056 | ) | $ | (19,635 | ) | |||
| Net loss per share attributed to common stockholders: | |||||||||||||||
| Basic | $ | (0.07 | ) | $ | (0.06 | ) | $ | (0.27 | ) | $ | (0.26 | ) | |||
| Diluted | $ | (0.07 | ) | $ | (0.06 | ) | $ | (0.27 | ) | $ | (0.26 | ) | |||
| Weighted average number of common shares and equivalents: | |||||||||||||||
| Basic | 82,702,722 | 76,308,259 | 80,702,358 | 76,061,183 | |||||||||||
| Diluted | 82,702,722 | 76,308,259 | 80,702,358 | 76,061,183 | |||||||||||
| STEREOTAXIS, INC. | |||||||
| BALANCE SHEETS | |||||||
| (in thousands, except share amounts) | December 31, 2023 | December 31, 2022 | |||||
| (Unaudited) | |||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 19,818 | $ | 8,586 | |||
| Restricted cash - current | 525 | 525 | |||||
| Short-term investments | - | 19,844 | |||||
| Accounts receivable, net of allowance of $672 and $235 at 2023 and 2022, respectively | 3,822 | 5,090 | |||||
| Inventories, net | 8,426 | 7,876 | |||||
| Prepaid expenses and other current assets | 676 | 1,325 | |||||
| Total current assets | 33,267 | 43,246 | |||||
| Property and equipment, net | 3,304 | 3,831 | |||||
| Restricted cash | 219 | 744 | |||||
| Operating lease right-of-use assets | 4,982 | 5,384 | |||||
| Prepaid and other non-current assets | 137 | 208 | |||||
| Total assets | $ | 41,909 | $ | 53,413 | |||
| Liabilities and stockholders' equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 3,190 | $ | 3,270 | |||
| Accrued liabilities | 2,972 | 3,306 | |||||
| Deferred revenue | 6,657 | 7,342 | |||||
| Current portion of operating lease liabilities | 428 | 373 | |||||
| Total current liabilities | 13,247 | 14,291 | |||||
| Long-term deferred revenue | 1,637 | 1,654 | |||||
| Operating lease liabilities | 5,062 | 5,488 | |||||
| Other liabilities | 43 | 51 | |||||
| Total liabilities | 19,989 | 21,484 | |||||
| Series A - Convertible preferred stock: | |||||||
| Convertible preferred stock, Series A, par value $0.001; 22,358 and 22,383 shares outstanding at 2023 and 2022 | 5,577 | 5,583 | |||||
| Stockholders' equity: | |||||||
| Convertible preferred stock, Series B, par value $0.001; 10,000,000 shares authorized, 5,610,121 shares outstanding at 2022 | - | 6 | |||||
| Common stock, par value $0.001; 300,000,000 shares authorized, 80,949,697 and 74,874,459 shares issued at 2023 and 2022, respectively | 81 | 75 | |||||
| Additional paid-in capital | 554,148 | 543,438 | |||||
| Treasury stock, 4,015 shares at 2023 and 2022 | (206 | ) | (206 | ) | |||
| Accumulated deficit | (537,680 | ) | (516,967 | ) | |||
| Total stockholders' equity | 16,343 | 26,346 | |||||
| Total liabilities and stockholders' equity | $ | 41,909 | $ | 53,413 | |||
